Privacy Policy

Incyte Corporation ("Incyte") is committed to maintaining the privacy and security of your personally identifiable information collected through this website. This Privacy Policy sets forth Incyte's information collection and dissemination practices in connection with the website and applies solely to the information collected through the website. This Privacy Policy does not address personally identifiable information that you provide to us in other contexts. By using the website, you signify your acceptance of this Privacy Policy.

Personally identifiable information

With respect to the website, Incyte will only collect, store or use personally identifiable information (that is, any information by which you can be identified, such as name, address, email address, and telephone number, which we refer to as "Your Information"), when it is voluntarily submitted to us. You have the option not to provide any of Your Information to us. If you do provide Your Information to us, Your Information may be used to fulfill your request for information, to provide you with other information or services, to market future products and services which we think may be of interest to you, to communicate with you for other purposes, to respond to requests you may make of us, and from time to time, we may refer to Your Information to better understand your needs and how we can improve the website's services and we may use Your Information within the company for performing marketing studies or other analyses. We will not sell Your Information to any other company or organization. We may share Your Information with other companies or organizations that work with, or on behalf of, Incyte to provide products and services, but subject to limitations on their use or disclosure.

If you choose not to provide the information we may request, you can still visit most of the website, but you may be unable to access certain options and services. In general, you can visit the website without telling us who you are or revealing any personal information about yourself. We may track the total number of visitors to our site, the number of visitors to each page of our site, and the domain names of our visitors' Internet service providers and analyze this data for trends and statistics, but the individual user remains anonymous. From time to time we may share such aggregated data with third parties assisting us in market research.

You may update Your Information and opt out of receiving certain communications or have us stop contacting you by accessing your registration or profile. You may also opt out of receiving emails and other communications from us by using the features or other communication means contained in emails sent to you. Such requests will be subject to any applicable legal and ethical reporting or document filing or retention obligations.

Use of cookies

We may use the data we obtain through the use of cookies (small data files that a website transfers to your browser to store on your computer when you access a website) to customize your site experience by anticipating the information and services that may be of interest to you. We may also analyze the information collected with cookie technology to help us improve the functioning of the website by monitoring traffic in popular areas and to modify the services and information we provide to meet customer demand. We may link the data available to us through the use of cookies to the personally identifiable information and health-related information that you may choose to provide elsewhere on the website. We use the information we collect through the use of cookies for our business purposes, including operation of the website. To disable or limit the use of cookies, please refer to the options provided by your browser. If you do so, however, some portions of the website may not work properly.

Release in limited circumstances

In certain limited circumstances, Incyte may be required to release Your Information in response to a court order, subpoena, search warrant, law, or regulation. We also reserve the right to cooperate with law enforcement authorities in investigating and prosecuting users who violate our rules or engage in behavior that is illegal or harmful to other websites.

Privacy of children

We are committed to protecting the privacy of children. This site is not intended, or designed, to attract children under the age of eighteen.

Security measures

The website has security measures in place, including the use of industry-standard secure socket layer encryption (SSL), to protect the confidentiality of any of Your Information that you volunteer. However, to take advantage of this, your browser must support encryption protection. Regardless of the precautions taken by you or by us, perfect security does not exist on the Internet. We cannot ensure or warrant the security of any information you transmit to us, and you transmit such information at your own risk.

Links to other sites

As a convenience to our visitors, the website currently contains links to a number of sites that we believe may offer useful information. This Privacy Policy does not apply to those sites. We suggest contacting those sites directly for information on their privacy policies.

Additional information

The website is intended for use by United States residents only. Any personally identifiable information submitted at the website goes to Incyte in the United States and by submitting personally identifiable information to the website, you waive any rights you may have under any law of any other country or region.

Contact

If you have any comments or questions regarding our Privacy Policy, please contact us at support@incyte.com.

We may update this Privacy Policy from time to time. When we do update it, for your convenience, we will make the updated policy available on this page. This Privacy Policy was last updated November 2011.

Expand +

Indications and Usage

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.
 
IMPORTANT SAFETY INFORMATION
 
INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.